Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
FTSE 100 Falls as US-Iran Conflict Drives Oil Prices Higher 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Australia Current Account Deficit Widens to A$27.2 Billion 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Gold Prices Slide as Iran Conflict Fuels Fed Rate Hike Bets 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Global Markets Brace for Fed Rate Hike as Oil Tops $91 
Asian Stocks Slip as Fed Rate Hike Bets and Oil Surge Weigh 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
South Korea Inflation Rises to 3.1% in August 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
RBNZ Raises Interest Rate to 2.75%, Kiwi Dollar Slides 
Add as a preferred source on Google
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
